Helmholtz Gemeinschaft


Evaluating uncertainty in signaling networks using logical modeling

[thumbnail of Original Article]
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
[thumbnail of Supplementary Material]
PDF (Supplementary Material) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:Evaluating uncertainty in signaling networks using logical modeling
Creators Name:Thobe, K., Kuznia, C., Sers, C. and Siebert, H.
Abstract:Systems biology studies the structure and dynamics of biological systems using mathematical approaches. Bottom-up approaches create models from prior knowledge but usually cannot cope with uncertainty, whereas top-down approaches infer models directly from data using statistical methods but mostly neglect valuable known information from former studies. Here, we want to present a workflow that includes prior knowledge while allowing for uncertainty in the modeling process. We build not one but all possible models that arise from the uncertainty using logical modeling and subsequently filter for those models in agreement with data in a top-down manner. This approach enables us to investigate new and more complex biological research questions, however, the encoding in such a framework is often not obvious and thus not easily accessible for researcher from life sciences. To mitigate this problem, we formulate a pipeline with specific templates to address some research questions common in signaling network analysis. To illustrate the potential of this approach, we applied the pipeline to growth factor signaling processes in two renal cancer cell lines. These two cell lines originate from similar tissue, but surprisingly showed a very different behavior toward the cancer drug Sorafenib. Thus our aim was to explore differences between these cell lines regarding three sources of uncertainty in one analysis: possible targets of Sorafenib, crosstalk between involved pathways, and the effect of a mutation in mammalian target of Rapamycin (mTOR) in one of the cell lines. We were able to show that the model pools from the cell lines are disjoint, thus the discrepancies in behavior originate from differences in the cellular wiring. Also the mutation in mTOR is not affecting its activity in the pathway. The results on Sorafenib, while not fully clarifying the mechanisms involved, illustrate the potential of this analysis for generating new hypotheses.
Keywords:Systems Biology, Logical Modeling, Model Checking, Constraint Based Modeling, Signaling Pathways
Source:Frontiers in Physiology
Publisher:Frontiers Media SA
Page Range:1335
Date:October 2018
Official Publication:https://doi.org/10.3389/fphys.2018.01335
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library